Abstract
Genome-wide association studies identified the BIN1 locus as a leading modulator of genetic risk in Alzheimer's disease (AD). One limitation in understanding BIN1's contribution to AD is its unknown function in the brain. AD-associated BIN1 variants are generally noncoding and likely change expression. Here, we determined the effects of increasing expression of the major neuronal isoform of human BIN1 in cultured rat hippocampal neurons. Higher BIN1 induced network hyperexcitability on multielectrode arrays, increased frequency of synaptic transmission, and elevated calcium transients, indicating that increasing BIN1 drives greater neuronal activity. In exploring the mechanism of these effects on neuronal physiology, we found that BIN1 interacted with L-type voltage-gated calcium channels (LVGCCs) and that BIN1–LVGCC interactions were modulated by Tau in rat hippocampal neurons and mouse brain. Finally, Tau reduction prevented BIN1-induced network hyperexcitability. These data shed light on BIN1's neuronal function and suggest that it may contribute to Tau-dependent hyperexcitability in AD.
Article and author information
Author details
Funding
National Institutes of Health (RF1AG059405)
- Erik D Roberson
National Institutes of Health (R01NS075487)
- Erik D Roberson
National Institutes of Health (R01MH114990)
- Jeremy J Day
National Institutes of Health (T32NS095775)
- Yuliya Voskobiynyk
National Institutes of Health (T32NS061788)
- Jonathan R Roth
Alzheimer's Association
- Erik D Roberson
Weston Brain Institute
- Jonathan R Roth
- Travis Rush
- Erik D Roberson
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#20450) of the University of Alabama at Birmingham. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Alabama at Birmingham.
Reviewing Editor
- John D. Fryer, Mayo Clinic, United States
Publication history
- Received: March 29, 2020
- Accepted: July 12, 2020
- Accepted Manuscript published: July 13, 2020 (version 1)
- Version of Record published: July 30, 2020 (version 2)
Copyright
© 2020, Voskobiynyk et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,957
- Page views
-
- 298
- Downloads
-
- 3
- Citations
Article citation count generated by polling the highest count across the following sources: PubMed Central, Crossref, Scopus.